Can Competitors
| CANF Stock | USD 2.10 0.05 2.44% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Can Fite competition on your existing holdings.
Can |
Can Fite Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Can Fite and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Can and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Can Fite Biopharma does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Can Stock performing well and Can Fite Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Can Fite's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ICCC | 1.74 | 0.13 | (0.03) | (0.06) | 2.33 | 3.40 | 21.64 | |||
| CGEN | 2.69 | (0.67) | 0.00 | (0.17) | 0.00 | 6.84 | 16.24 | |||
| EVGN | 3.67 | (1.14) | 0.00 | (3.09) | 0.00 | 7.50 | 36.00 | |||
| CLGN | 2.44 | (0.38) | 0.00 | (0.19) | 0.00 | 4.69 | 14.36 | |||
| PLX | 3.15 | 1.10 | 0.27 | (1.33) | 2.38 | 10.00 | 20.38 | |||
| CRVS | 3.61 | 1.05 | 0.28 | 0.79 | 2.98 | 9.38 | 23.11 | |||
| ALDX | 2.77 | (0.33) | 0.00 | (0.08) | 0.00 | 6.69 | 22.45 | |||
| GMDA | 3.41 | (0.08) | 0.00 | 0.60 | 0.00 | 6.81 | 28.30 | |||
| CKPT | 3.18 | 0.94 | 0.23 | 2.59 | 3.01 | 7.91 | 19.17 | |||
| CADL | 3.19 | (0.46) | 0.00 | (0.16) | 0.00 | 6.63 | 25.71 |
Cross Equities Net Income Analysis
Compare Can Fite Biopharma and related stocks such as ImmuCell, Compugen, and Evogene Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICCC | (1000 K) | (409.5 K) | 89.5 K | 117.4 K | (167.2 K) | 1.2 M | 508.4 K | (168 K) | (2.3 M) | (1.3 M) | (1 M) | (78 K) | (2.5 M) | (5.8 M) | (5.5 M) |
| CGEN | (8.1 M) | (12 M) | (13.6 M) | (14.1 M) | (11.1 M) | (20.2 M) | (31.5 M) | (37.1 M) | (22.6 M) | (27.3 M) | (27.3 M) | (32.9 M) | (33.7 M) | (18.8 M) | (19.7 M) |
| EVGN | 645 K | 645 K | (2.5 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (19.1 M) | (23.4 M) | (27.8 M) | (26.6 M) | (23.9 M) | (25.1 M) |
| CLGN | (4.6 M) | (4.6 M) | (4.6 M) | (4.7 M) | (3.3 M) | (4.8 M) | (7.2 M) | (6.1 M) | (6.2 M) | (14.7 M) | (5.8 M) | 409 K | (16.8 M) | (7 M) | (7.4 M) |
| PLX | 131.7 K | (36.5 M) | (11.6 M) | (27.8 M) | (29.9 M) | 58 M | (29.4 M) | (85.3 M) | (26.5 M) | (26.2 M) | (14.9 M) | (34 M) | (14.9 M) | 8.3 M | 8.7 M |
| CRVS | (175.6 K) | (175.6 K) | (175.6 K) | (175.6 K) | (175.6 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (38.2 M) | (50 M) | (27 M) | (28.4 M) |
| ALDX | (2.4 M) | (2.4 M) | (23.1 M) | 13.1 M | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (59.3 M) | (61.4 M) | (37.5 M) | (39.4 M) |
| CKPT | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (22.5 M) | (22.7 M) | (36.4 M) | (24.6 M) | (23 M) | (56.6 M) | (66.9 M) | (51.8 M) | (54.4 M) |
| CADL | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (22.2 M) | (36.1 M) | (2.9 M) | (37.9 M) | (36 M) |
| BRTX | (2.3 M) | (4.1 M) | (6.5 M) | (5.8 M) | (5.6 M) | (7.9 M) | (8.6 M) | (9.4 M) | (12.5 M) | (14.6 M) | (12.3 M) | (29.9 M) | (18 M) | (10.4 M) | (10.9 M) |
| XTLB | (12.7 M) | (1.2 M) | (1.4 M) | (2.5 M) | (2.5 M) | (4.3 M) | (2.5 M) | (781 K) | 3 M | (1.3 M) | (616 K) | 1.9 M | (2.3 M) | (1.8 M) | (1.9 M) |
| CING | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (11.4 M) | (7.3 M) | (20.7 M) | (17.9 M) | (23.5 M) | (24.7 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (7 M) | (7.4 M) |
| RNAZ | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (764.1 K) | (2.7 M) | (6.9 M) | (35.1 M) | (18.5 M) | (19.5 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.7 M) | (5.8 M) | (9.5 M) | (48.3 M) | (28.2 M) | (32.4 M) | (30.8 M) |
| RVPH | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (846.8 K) | (3.8 M) | (8.5 M) | (24.3 M) | (39.3 M) | (37.3 M) |
| ATXI | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (3.2 M) | (12.3 M) | (21.3 M) | (25.6 M) | (5.1 M) | (3.7 M) | 2 M | (10.4 M) | (10.9 M) |
| ORMP | (50 K) | (1.6 M) | (3.3 M) | (4.2 M) | (5.7 M) | (7.2 M) | (11 M) | (10.5 M) | (12.7 M) | (14.4 M) | (11.5 M) | (22.2 M) | (37.8 M) | 5.5 M | 5.8 M |
| MDWD | (6.2 M) | (6.2 M) | 10.9 M | (15.4 M) | (18.9 M) | (22.1 M) | (18.9 M) | (22.1 M) | (1.1 M) | 3.7 M | (9.6 M) | (13.6 M) | (19.6 M) | (6.7 M) | (7.1 M) |
| BLRX | 2.1 M | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (18.5 M) | (26.8 M) | (30.9 M) | (28.1 M) | (18.9 M) | (60.6 M) | (57.6 M) |
Can Fite Biopharma and related stocks such as ImmuCell, Compugen, and Evogene Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Can Fite Biopharma financial statement analysis. It represents the amount of money remaining after all of Can Fite Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Can Fite Competitive Analysis
The better you understand Can Fite competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Can Fite's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Can Fite's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Can Fite Competition Performance Charts
Five steps to successful analysis of Can Fite Competition
Can Fite's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Can Fite Biopharma in relation to its competition. Can Fite's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Can Fite in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Can Fite's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Can Fite Biopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Can Fite position
In addition to having Can Fite in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Can Fite Correlation with its peers. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.